A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors (NCT06384807)
A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Site-113 — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Site-113 — Duarte, California
- Site-112 — La Jolla, California
- Site-111 — Palo Alto, California
- Site-114 — Washington D.C., District of Columbia
- Site-103 — Miami, Florida
- Site-105 — Orlando, Florida
- Site-115 — Tampa, Florida
- Site-110 — Augusta, Georgia
- Site-109 — Detroit, Michigan
- Site-101 — St Louis, Missouri
- Site-117 — New York, New York
- Site-116 — Oklahoma City, Oklahoma
- Site-108 — Philadelphia, Pennsylvania
- Site-107 — Nashville, Tennessee
- Site-104 — Dallas, Texas
- Site-106 — West Valley City, Utah
- Site-102 — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (203) 404-0410
Email: clinicaltrials@biohavenpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.